Acquisition - March 15, 2017
The new Teva grows stronger – in Norway
In August last year Teva completed its acquisition of Actavis Generics and the new Teva in Norway will be among the 15 largest companies in the country. The new company will be named Teva and will be located at Teva’s facilities in Hagaløkkveien in Asker. Employees from Actavis moved in with the Teva team in […]
Clinical Trials - January 11, 2016
Active Biotech’s partner amend trial design
Active Biotech’s partner Teva Pharmaceutical Industries will amend the trial design in a Phase 2 study of laquinimod in Huntington’s disease. The amendment consists of dropping the highest of three doses (1.5 mg/day) in the trial while keeping two remaining active doses (0.5 and 1 mg/day) unchanged. This is a precautionary measure in the interest […]
Intellectual Property - September 3, 2014
AstraZeneca lost patent controversy
Teva has announced that the UK High Court gives positive judgment in the company’s patent case against AstraZeneca. The case regards the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca’s fixed dose formoterol/budesonide combination product, Symbicort. Teva said that the court agreed with Teva that AstraZeneca’s patent covering […]
Clinical Trials - August 15, 2014
Active Biotech’s partner Teva starts laquinimod clinical trial
Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Teva started a global research collaboration in the summer of 2013 to develop laquinimod as a treatment for Huntington’s disease. Earlier this year, […]
Drug Development Pharma - May 23, 2014
CHMP says no to Laquinimod
Teva Pharmaceutical and Active Biotech has announced that the Committee for Medicinal Products for Human Use’s confirmed its earlier opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis in the European Union at this time. According to a statement from Active Biotech, both companies remain committed to the NERVENTRA (laquinimod) clinical development program for […]
Collaboration - January 27, 2014
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva Pharmaceutical Industries and Active Biotech has announced that both companies remain committed to the NERVENTRA(laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The […]
